Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens

NCT06622057 is registered in ClinicalTrials.gov with InnoPharmax Inc. as lead sponsor.

NCT NCT06622057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06622057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens
Lead sponsor
InnoPharmax Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 9, 2026
Completion date
December 31, 2028
Enrollment
240 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc)